These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 17994638)

  • 1. Activity-dependent neurotrophic factor, ADNF, determines the structure characteristics of Colivelin, a fusion protein of ADNF9 and Humanin analog.
    Arakawa T; Niikura T; Arisaka F; Kita Y
    J Pept Sci; 2008 May; 14(5):631-6. PubMed ID: 17994638
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Short neuroprotective peptides, ADNF9 and NAP, are structurally disordered and monomeric in PBS.
    Arakawa T; Niikura T; Arisaka F; Kita Y
    Int J Biol Macromol; 2009 Jul; 45(1):8-11. PubMed ID: 19447252
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of a femtomolar-acting humanin derivative named colivelin by attaching activity-dependent neurotrophic factor to its N terminus: characterization of colivelin-mediated neuroprotection against Alzheimer's disease-relevant insults in vitro and in vivo.
    Chiba T; Yamada M; Hashimoto Y; Sato M; Sasabe J; Kita Y; Terashita K; Aiso S; Nishimoto I; Matsuoka M
    J Neurosci; 2005 Nov; 25(44):10252-61. PubMed ID: 16267233
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The structure analysis of Humanin analog, AGA-(C8R)HNG17, by circular dichroism and sedimentation equilibrium: comparison with the parent molecule.
    Arisaka F; Niikura T; Arakawa T; Kita Y
    Int J Biol Macromol; 2008 Aug; 43(2):88-93. PubMed ID: 18456318
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure analysis of activity-dependent neurotrophic factor 9 by circular dichroism and sedimentation equilibrium.
    Arakawa T; Niikura T; Tajima H; Arisaka F; Kita Y
    J Mol Neurosci; 2007; 33(3):262-7. PubMed ID: 17952635
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The secondary structure analysis of a potent Ser14Gly analog of antiAlzheimer peptide, Humanin, by circular dichroism.
    Arakawa T; Niikura T; Tajima H; Kita Y
    J Pept Sci; 2006 Oct; 12(10):639-42. PubMed ID: 16835886
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure changes of natively disordered Humanin in the presence of lipid.
    Hirano A; Shiraki K; Niikura T; Arakawa T; Kita Y
    Int J Biol Macromol; 2010 Apr; 46(3):375-9. PubMed ID: 20116397
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neuroprotection against neurodegenerative diseases: development of a novel hybrid neuroprotective peptide Colivelin.
    Chiba T; Nishimoto I; Aiso S; Matsuoka M
    Mol Neurobiol; 2007 Feb; 35(1):55-84. PubMed ID: 17519506
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Solution structure of Ser14Gly-humanin, a potent rescue factor against neuronal cell death in Alzheimer's disease.
    Benaki D; Zikos C; Evangelou A; Livaniou E; Vlassi M; Mikros E; Pelecanou M
    Biochem Biophys Res Commun; 2006 Oct; 349(2):634-42. PubMed ID: 16945331
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activity-dependent neurotrophic factor: structure-activity relationships of femtomolar-acting peptides.
    Brenneman DE; Hauser J; Neale E; Rubinraut S; Fridkin M; Davidson A; Gozes I
    J Pharmacol Exp Ther; 1998 May; 285(2):619-27. PubMed ID: 9580606
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The biological activity of Humanin analogs correlates with structure stabilities in solution.
    Arakawa T; Niikura T; Kita Y
    Int J Biol Macromol; 2011 Jul; 49(1):93-7. PubMed ID: 21510972
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Humanin structural versatility and interaction with model cerebral cortex membranes.
    Pistolesi S; Rossini L; Ferro E; Basosi R; Trabalzini L; Pogni R
    Biochemistry; 2009 Jun; 48(22):5026-33. PubMed ID: 19378954
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structure of three Humanin peptides with different activities upon interaction with liposome.
    Hirano A; Shiraki K; Niikura T; Arakawa T; Kita Y
    Int J Biol Macromol; 2011 Mar; 48(2):360-3. PubMed ID: 21215775
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nuclear factor-kappaB mediates the cell survival-promoting action of activity-dependent neurotrophic factor peptide-9.
    Glazner GW; Camandola S; Mattson MP
    J Neurochem; 2000 Jul; 75(1):101-8. PubMed ID: 10854252
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structural and dynamical studies of Humanin in water and TFE/water mixture: a molecular dynamics simulation.
    Mehrnejad F; Chaparzadeh N
    J Biomol Struct Dyn; 2008 Oct; 26(2):255-62. PubMed ID: 18597547
    [TBL] [Abstract][Full Text] [Related]  

  • 16. D-Ser-containing humanin shows promotion of fibril formation.
    Hayashi K; Sasabe J; Chiba T; Aiso S; Utsunomiya-Tate N
    Amino Acids; 2012 Jun; 42(6):2293-7. PubMed ID: 21735222
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Humanin and colivelin: neuronal-death-suppressing peptides for Alzheimer's disease and amyotrophic lateral sclerosis.
    Matsuoka M; Hashimoto Y; Aiso S; Nishimoto I
    CNS Drug Rev; 2006; 12(2):113-22. PubMed ID: 16958985
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Solution structure of humanin, a peptide against Alzheimer's disease-related neurotoxicity.
    Benaki D; Zikos C; Evangelou A; Livaniou E; Vlassi M; Mikros E; Pelecanou M
    Biochem Biophys Res Commun; 2005 Apr; 329(1):152-60. PubMed ID: 15721287
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Zinc(II) binds to the neuroprotective peptide humanin.
    Armas A; Sonois V; Mothes E; Mazarguil H; Faller P
    J Inorg Biochem; 2006 Oct; 100(10):1672-8. PubMed ID: 16844225
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The multiple T-maze in vivo testing of the neuroprotective effect of humanin analogues.
    Kunesová G; Hlavácek J; Patocka J; Evangelou A; Zikos C; Benaki D; Paravatou-Petsotas M; Pelecanou M; Livaniou E; Slaninova J
    Peptides; 2008 Nov; 29(11):1982-7. PubMed ID: 18647630
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.